I agree that this site is using cookies. You can find further informations here.
X
Wied, Magnus C.
133  results:
Search for persons X
?
1

Atomic structural changes in the formation of transition me..:

Skjærvø, Susanne Linn ; Anker, Andy S. ; Wied, Magnus C....
Chemical Science.  14 (2023)  18 - p. 4806-4816 , 2023
Link: https://doi.org/10.1039/..
 
?
2

Atomic structural changes in the formation of transition me..:

Skjærvø, Susanne Linn ; Anker, Andy S ; Wied, Magnus C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171188/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Atomic structural changes in the formation of transition me..:

Skjærvø, Susanne Linn ; Anker, Andy S ; Wied, Magnus C...
info:eu-repo/semantics/altIdentifier/issn/2041-6520.  , 2023
Link: https://bib-pubdb1.desy...
 
?
4

The validity of biomarkers as surrogate endpoints in Alzhei..:

Wied, C. C. Gispen-De ; Kritsidima, M. ; Elferink, A.J.A.
The Journal of nutrition, health and aging.  13 (2009)  4 - p. 376-387 , 2009
Link: https://doi.org/10.1007/..
 
?
5

Impaired flexibility of the hypothalamic-pituitaryadrenal s..:

Jansen, L.M.C. ; Wied, C.C.Gispen-de ; Kahn, R.S.
European Neuropsychopharmacology.  8 (1998)  - p. S218 , 1998
Link: https://doi.org/10.1016/..
 
?
6

Stimulation of the pituitary-adrenal system with graded dos..:

Wied, C.C.Gispen-de ; Kok, F.W. ; Koppeschaar, H.P.F....
European Neuropsychopharmacology.  3 (1993)  4 - p. 533-541 , 1993
Link: https://doi.org/10.1016/..
 
?
7

The effects of olanzapine on neuroendocrine responses induc..:

Scheepers, F.E. ; Gispen de Wied, C.C. ; Kahn, R.S.
European Neuropsychopharmacology.  10 (2000)  - p. 132-134 , 2000
Link: https://doi.org/10.1016/..
 
?
8

Thalamic volumes in patients with schizophrenia, healthy si..:

Staal, W.G. ; HulshoffPol, H.E. ; Schnack, H.G....
Schizophrenia Research.  29 (1998)  1-2 - p. 139-140 , 1998
Link: https://doi.org/10.1016/..
 
?
9

Factors Contributing to the Efficacy-Effectiveness Gap in t..:

Schuller, Y. ; Hollak, C. E. M. ; Gispen-de Wied, C. C...
Drugs.  77 (2017)  13 - p. 1461-1472 , 2017
Link: https://doi.org/10.1007/..
 
?
10

Placebo response in antipsychotic trials of patients with a..:

Welten, C.C.M. ; Koeter, M.W.J. ; Wohlfarth, T....
European Neuropsychopharmacology.  25 (2015)  7 - p. 1018-1026 , 2015
Link: https://doi.org/10.1016/..
 
?
11

Net gain analysis, an addition to responder analysis – The ..:

Welten, C.C.M. ; Koeter, M.W.J. ; Wohlfarth, T.D....
Regulatory Toxicology and Pharmacology.  73 (2015)  1 - p. 227-231 , 2015
Link: https://doi.org/10.1016/..
 
?
12

EU marketing authorization review of orphan and non-orphan ..:

Putzeist, M. ; Mantel-Teeuwisse, A.K. ; Llinares, J....
Drug Discovery Today.  18 (2013)  19-20 - p. 1001-1006 , 2013
Link: https://doi.org/10.1016/..
 
?
13

The risk-based approach to ATMP development – Generally acc..:

Kooijman, M. ; van Meer, P.J.K. ; Gispen-de Wied, C.C....
Regulatory Toxicology and Pharmacology.  67 (2013)  2 - p. 221-225 , 2013
Link: https://doi.org/10.1016/..
 
?
14

Drug development for exceptionally rare metabolic diseases:..:

Putzeist, Michelle ; Mantel-Teeuwisse, Aukje K ; Wied, Christine C Gispen-de...
Orphanet Journal of Rare Diseases.  8 (2013)  1 - p. , 2013
Link: https://doi.org/10.1186/..
 
?
15

Automated high precision secondary pH measurements:

Bastkowski, F. ; Jakobsen, P. T. ; Stefan, F....
Review of Scientific Instruments.  84 (2013)  4 - p. , 2013
Link: https://doi.org/10.1063/..
 
1-15